Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for DFTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 918.68M
March 31, 2026 278.85M
December 31, 2025 332.33M
September 30, 2025 130.60M
June 30, 2025 185.40M
March 31, 2025 222.81M
December 31, 2024 241.45M
September 30, 2024 262.19M
June 30, 2024 202.05M
March 31, 2024 196.06M
December 31, 2023 78.13M
September 30, 2023 95.98M
June 30, 2023 105.97M
March 31, 2023 130.34M
December 31, 2022 150.92M
September 30, 2022 153.59M
June 30, 2022 124.50M
March 31, 2022 136.80M
December 31, 2021 151.66M
Date Value
September 30, 2021 166.05M
June 30, 2021 151.66M
March 31, 2021 187.59M
December 31, 2020 83.27M
September 30, 2020 19.64M
June 30, 2020 27.74M
March 31, 2020 23.84M
August 31, 2019 2.738M
May 31, 2019 3.402M
February 28, 2019 3.524M
November 30, 2018 3.396M
August 31, 2018 3.525M
May 31, 2018 3.252M
February 28, 2018 3.481M
November 30, 2017 3.677M
August 31, 2017 3.571M
May 31, 2017 3.811M
February 28, 2017 2.19M
November 30, 2016 0.7559M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 1.044M
CNBX Pharmaceuticals, Inc. -2.660M
GB Sciences, Inc. --
Arvinas, Inc. 562.20M
Fulcrum Therapeutics, Inc. 310.70M

Shareholders Equity (Quarterly) Related Metrics